Will ATAI price a follow-on equity offering of at least $200M at a discount of less than 20% to prior-close by 2026-12-31?

Three-factor decomposition: (1) P(ATAI prices any offering in 2026) ~75% — burn trajectory forces raise, but strategic partnership or 2027 deferral are plausible alternatives; (2) P(offering ≥$200M given raise) ~60% — $200M is at the upper end of sub-$2B market cap biotech raise sizes, management may prefer two $125-150M tranches; (3) P(discount <20% given size ≥$200M) ~75% — Breakthrough + rally + strong fundamentals support tight pricing but volatile rallied names carry premium discount. Joint 0.75 x 0.60 x 0.75 = 0.34. Add +0.04 for index-inclusion passive demand support. Net 0.38.

The simultaneous joint condition (size AND discount) is the binding constraint. Historically, biotechs that raise larger amounts accept larger discounts to ensure placement. Cross-reference: in 2024-2025 biotech data, approximately 35-45% of Breakthrough-designated Phase 3 programs with recent rallies hit both thresholds on the same raise. ATAI-specific factors tilt slightly positive (debt-free, single-asset focus, strong Phase 2b data) but single-asset concentration may deter large institutional allocators forcing slightly deeper discount. Settle at 0.35.

More conservative. The 341% YTD rally is a double-edged sword for placement economics: it creates the window AND the placement risk (underwriters worry about rally-unwind post-deal). Typical discount for volatile rallied biotech names in the 200%+ YTD cohort is 15-25% — bimodal with many landing 20-25%. 'Less than 20%' is a hard threshold that splits the typical discount distribution. Also, convertible debt structure is increasingly common for Phase 3 biotechs to minimize dilution — convertibles often don't count as 'offering with less than 20% discount' under the resolution criterion. Net 0.32.

Base rate for biotech follow-on hitting both size and discount thresholds simultaneously: approximately 35-50% for well-positioned programs. ATAI tilts slightly negative on the joint threshold because 341% rally volatility favors larger discounts. Typical outcome: $200-250M raise at 15-25% discount, which is borderline on the 20% threshold. Split roughly 50/50 on the discount side. Adjusted base rate 0.35.

The committee's finding that 'Funding Window Closes Amid Phase 3 Interim Stall' is a 10-20% probability SEVERE scenario implies the optimistic scenario (favorable raise) is not the modal outcome. Adding in the possibility of deferred 2027 raise (~20%) and non-equity structures (convertibles, royalty financing ~15%), the probability of a specifically 2026-dated equity raise at favorable terms compresses to 0.30.

Balanced view. Breakthrough status + validated Phase 2b + debt-free + rally creates favorable underwriter conditions. But the AND joint on size AND discount is the compression. Credit it as 40% base rate with -5% for single-asset concentration investor concern. Net 0.36.

Biotech follow-ons for Breakthrough Phase 3 programs with strong rallies typically price at 10-20% discount and $150-300M range. Hitting both $200M+ AND <20% discount simultaneously is ~35-45% base rate. Middle of range 0.35.

Conditional chain: P(raise 2026) ~70%, P(size ≥$200M) ~55%, P(discount <20%) ~80%. Joint 0.70 x 0.55 x 0.80 = 0.308. Round to 0.33.

Program-specific tailwinds (Breakthrough, rally, debt-free) tilt slightly above base rate. Anchor 0.37. Committee's FUNDING_FRAGILITY STRETCHED signal means raise is near-certain but favorable-terms component is 35-45% base rate.